BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27756161)

  • 1. Modeling the chronic lymphocytic leukemia microenvironment in vitro.
    Crassini K; Shen Y; Mulligan S; Giles Best O
    Leuk Lymphoma; 2017 Feb; 58(2):266-279. PubMed ID: 27756161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.
    Cols M; Barra CM; He B; Puga I; Xu W; Chiu A; Tam W; Knowles DM; Dillon SR; Leonard JP; Furman RR; Chen K; Cerutti A
    J Immunol; 2012 Jun; 188(12):6071-83. PubMed ID: 22593611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
    Hayden RE; Pratt G; Roberts C; Drayson MT; Bunce CM
    Leuk Lymphoma; 2012 Apr; 53(4):537-49. PubMed ID: 21812539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis.
    van Attekum MHA; van Bruggen JAC; Slinger E; Lebre MC; Reinen E; Kersting S; Eldering E; Kater AP
    Haematologica; 2017 Dec; 102(12):2069-2076. PubMed ID: 28971904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL.
    Chen Y; Peubez C; Smith V; Xiong S; Kocsis-Fodor G; Kennedy B; Wagner S; Balotis C; Jayne S; Dyer MJS; Macip S
    J Cell Mol Med; 2019 Jan; 23(1):340-348. PubMed ID: 30353642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
    Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
    Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.
    Ramsay AD; Rodriguez-Justo M
    Br J Haematol; 2013 Jul; 162(1):15-24. PubMed ID: 23617880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions.
    Burger JA; Gandhi V
    Blood; 2009 Sep; 114(12):2560-1; author reply 2561-2. PubMed ID: 19762501
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Slinger E; Thijssen R; Kater AP; Eldering E
    Leukemia; 2017 Dec; 31(12):2601-2607. PubMed ID: 28462919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization.
    Natoni A; O'Dwyer M; Santocanale C
    Methods Mol Biol; 2013; 986():217-26. PubMed ID: 23436415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.
    Herishanu Y; Katz BZ; Lipsky A; Wiestner A
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):173-206. PubMed ID: 23561469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
    Crassini K; Stevenson WS; Mulligan SP; Best OG
    Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.
    Choi MY; Kashyap MK; Kumar D
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):40-53. PubMed ID: 27742071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
    Hegde GV; Peterson KJ; Emanuel K; Mittal AK; Joshi AD; Dickinson JD; Kollessery GJ; Bociek RG; Bierman P; Vose JM; Weisenburger DD; Joshi SS
    Mol Cancer Res; 2008 Dec; 6(12):1928-36. PubMed ID: 19074837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.
    Valsecchi R; Coltella N; Belloni D; Ponente M; Ten Hacken E; Scielzo C; Scarfò L; Bertilaccio MT; Brambilla P; Lenti E; Martinelli Boneschi F; Brendolan A; Ferrero E; Ferrarini M; Ghia P; Tonon G; Ponzoni M; Caligaris-Cappio F; Bernardi R
    Blood; 2016 Apr; 127(16):1987-97. PubMed ID: 26825709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli.
    Martinelli S; Maffei R; Fiorcari S; Quadrelli C; Zucchini P; Benatti S; Potenza L; Luppi M; Marasca R
    Leuk Res; 2017 Mar; 54():17-24. PubMed ID: 28092772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.
    Ferrer G; Bosch R; Hodgson K; Tejero R; Roué G; Colomer D; Montserrat E; Moreno C
    Br J Haematol; 2014 Feb; 164(4):570-8. PubMed ID: 24245956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
    Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
    Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.